Comparison
3 Methylglutaconic Aciduria Type Viia C5676967 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between 3 Methylglutaconic Aciduria Type Viia and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type Viia C5676967
A rare inherited metabolic disorder affecting mitochondrial function. It typically appears in infancy with developmental delay, movement problems, and muscle weakness. Management focuses on supportive care and addressing specific symptoms.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type Viia C5676967
0-2
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type Viia C5676967
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type Viia C5676967
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type Viia C5676967
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-viia-C5676967 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Developmental delay | Typically begins in infancy and may accompany movement problems and muscle weakness. | May occur with variable neurological features; onset is not limited to a stated age. | Moderate |
| Movement and muscle findings | Movement problems and muscle weakness are described as typical features. | Neurological features may occur, but muscle weakness is not specifically established. | Moderate |
| Kidney involvement | Kidney disease is not established by the supplied description. | Potential kidney involvement is described and may require monitoring. | High |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type Viia C5676967 when
Infant with developmental delay, movement problems, and weakness
This pattern aligns with the described infantile mitochondrial presentation.
Moderate
Suspected inherited metabolic disease
The condition is categorized as a rare inherited metabolic disorder.
High
Severe early course without a known chromosomal deletion
Severity is described as severe, but testing must confirm the cause.
Low
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Developmental delay with possible kidney findings
Kidney involvement is a described feature of the deletion syndrome.
Moderate
Suspected chromosomal deletion
The condition is defined by a recurrent deletion on chromosome 17.
High
Variable congenital presentation needing surveillance
Management emphasizes monitoring and supportive therapies.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Urine organic-acid analysis | May support 3-methylglutaconic aciduria; no cutoff is supplied. | No characteristic organic-acid result is established. | An abnormal metabolite result is not itself a diagnosis and needs specialist review. |
| Genetic or chromosomal testing | A disease-specific genetic result may be sought; exact gene evidence is not supplied. | Testing may identify a recurrent 17q12 deletion. | The specific genetic finding distinguishes etiology. |
| Kidney evaluation | No expected kidney abnormality is established here. | Assessment may be appropriate because kidney involvement is possible. | Findings require clinical correlation and do not alone confirm either condition. |
Prognosis comparison
3 Methylglutaconic Aciduria Type Viia C5676967
- Outcome
- A severe chronic course is described, but individual prognosis is not established.
- Factors
- Infancy onset, developmental delay, movement problems, and muscle weakness may influence needs.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- A moderate chronic course is described, with variable features.
- Factors
- Developmental, neurological, and possible kidney involvement may affect outlook.
Time frame: Both are chronic; exact milestones and survival data are not supplied.
Prognosis should be individualized after confirmed testing and clinical assessment.
Complications comparison
| Complication | Presentation |
|---|---|
| Neuromotor impairment | Movement problems and muscle weakness may substantially affect function. Neurological features may occur but are described as variable. Severity and functional impact are not quantified in the source. |
| Kidney complications | Not established from the supplied data. Potential kidney involvement warrants monitoring. The type, frequency, and severity are not specified. |
| Developmental complications | Early developmental delay is typical in the description. Developmental delays may occur and need individualized support. Neither outcome nor response to therapy is established. |
Patient education highlights
- HighDifferent causes
One is a rare inherited mitochondrial metabolic disorder; the other is a chromosomal deletion. Neither is communicable.
- HighTesting and confirmation
Names and symptoms do not confirm a diagnosis. Genetic and metabolic results need clinician interpretation.
- MediumSupportive care
Management is supportive, with symptom treatment for the metabolic disorder and monitoring plus therapies for the deletion.